drugset / Trial / NCT05882630
Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer
Phase 1/2
Unknown
39 enrolled
Fujian Cancer Hospital
Hunan Cancer Hospital · collabWuhan TongJi Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluates the effectiveness and safety of Surufatinib combined with Serplulimab plus chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Surufatinib combined with Serplulimab
Timeline
- Start
- 2023-06-01
- Primary completion
- 2025-06-01
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Serplulimab | Monoclonal antibody | 4.5 mg/kg | Intravenous |
| Subject | Surufatinib | Small molecule | — | Oral |